Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells 2,831 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 2,831 shares of the company’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $22.64, for a total value of $64,093.84. Following the completion of the sale, the chief financial officer now directly owns 46,799 shares in the company, valued at approximately $1,059,529.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Akero Therapeutics Trading Up 1.4 %

NASDAQ AKRO traded up $0.33 during trading hours on Thursday, hitting $24.62. 584,012 shares of the company’s stock were exchanged, compared to its average volume of 1,098,688. The business’s 50 day moving average is $20.79 and its 200-day moving average is $22.24. Akero Therapeutics, Inc. has a 12-month low of $11.25 and a 12-month high of $56.87. The firm has a market capitalization of $1.70 billion, a P/E ratio of -7.59 and a beta of -0.31. The company has a debt-to-equity ratio of 0.04, a quick ratio of 30.12 and a current ratio of 30.12.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, May 10th. The company reported ($0.90) earnings per share for the quarter, hitting the consensus estimate of ($0.90). As a group, analysts anticipate that Akero Therapeutics, Inc. will post -3.87 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on AKRO shares. UBS Group upped their target price on Akero Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Bank of America began coverage on Akero Therapeutics in a research note on Monday, April 22nd. They set a “neutral” rating and a $30.00 price objective on the stock. Wolfe Research began coverage on Akero Therapeutics in a research note on Tuesday. They set an “outperform” rating on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Akero Therapeutics in a research note on Wednesday. Finally, Evercore ISI decreased their price objective on Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 15th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.13.

Hedge Funds Weigh In On Akero Therapeutics

Several large investors have recently added to or reduced their stakes in AKRO. Orion Capital Management LLC purchased a new position in shares of Akero Therapeutics in the 3rd quarter worth about $51,000. Headlands Technologies LLC purchased a new position in shares of Akero Therapeutics in the 4th quarter worth about $28,000. Russell Investments Group Ltd. raised its holdings in shares of Akero Therapeutics by 2,366.0% in the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after purchasing an additional 1,183 shares during the period. Quarry LP raised its holdings in shares of Akero Therapeutics by 40.0% in the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock worth $41,000 after purchasing an additional 500 shares during the period. Finally, Strs Ohio raised its holdings in shares of Akero Therapeutics by 100.0% in the 4th quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $46,000 after purchasing an additional 1,000 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.